01 Jul Bio-Me Joins Medicen Working Group

Bio-Me will work in a network of more than 30 academic groups, biotech/pharma companies, CROs, and associations to understand interactions between drugs and the microbiome.

OSLO, Norway, July 1, 2022 – Bio-Me today announced it has become part of the Medicen Microbiome Drug Metabolism working group, an international initiative by leading academic, pharma and institutions to address the need for better understanding of drug-microbiome interactions. Recent publications have shown that many different drugs currently in use are metabolized by various gut bacteria. Certain gut bacteria can also influence the bioavailability of drugs and lead to un-wanted drug toxicity (Nature. 2019 Jun; 570(7762): 462–467).

The working group initiated by the Medicen Paris Region cluster comprises a network of more than 30 academic groups, biotech companies, CROs and associations, and includes 10 of the major pharma companies. The aim is to apply excellence in innovation to solving the challenges arising from drug-microbiome interactions to help develop tomorrow’s therapeutic solutions.

“Developing tools to measure how different gut bacteria influence drugs will be important both for improved utility of existing drugs, but also in formulating better, more personalized drugs in the future”, comments Michael Zimmermann, Group leader at EMBL and coleader of the working group.

Patrick Jimonet, Medicen project leader comments: “We welcome companies like Bio-Me into the Medicen initiative and look forward to working with them to accelerate the microbiome integration in the drug discovery and development process.”

Morten Isaksen, Founder of Bio-Me and its Chief Innovation Officer notes: “Bio-Me is excited to join this prestigious group of companies and leading scientists and important work for better, personalized healthcare in the future. We see that our PMP™ technology is perfectly suited to adapt information from this work into something that can have an immediate clinical relevance and improve patient care worldwide.”

The Precision Medicine market is expected to hit $140 bill by 2028 (https://www.biospace.com/article/precision-medicine-market-size-to-hit-us-140-69-bn-by-2028/).

Read external coverage here: https://nordiclifescience.org/bio-me-joins-medicen-initiative/?utm_source=rss&utm_medium=rss&utm_campaign=bio-me-joins-medicen-initiative.